Alafair Biosciences Awarded Synthetic Implantable Products Agreement With Premier, Inc. for VersaWrap Hydrogel Sheet
Alafair Biosciences Awarded Synthetic Implantable Products Agreement With Premier, Inc. for VersaWrap Hydrogel Sheet
AUSTIN, Texas, July 2, 2024 /PRNewswire/ -- Alafair Biosciences, Inc., is revolutionizing soft tissue protection with innovative hydrogel medical devices, today announced that its flagship product, VersaWrap Hydrogel Sheet (VersaWrap), has been awarded a national group purchasing agreement with Premier, Inc. Effective July 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for VersaWrap. VersaWrap is a class II medical device that allows tissues to glide and to remain untethered, thereby reducing reoperations and improving patient outcomes.
Alafair Biosciences, Inc.正在通過創新的水凝膠醫療器械革新軟組織保護，今天宣佈其旗艦產品VersaWrap水凝膠片（VersaWrap）已與Premier，Inc.獲得了一個國家採購協議。從2024年7月1日起生效的新協議允許Premier成員自行決定是否利用Premier爲VersaWrap預先談判的特別定價和條款。VersaWrap是一種二類醫療器械，可以使組織滑動並保持脫節，從而減少再次手術，改善患者的預後。
"We are honored that Premier and its members reviewed our technology and awarded Alafair an agreement," stated John Joyoprayitno, President & CEO of Alafair Biosciences. "This agreement provides a meaningful opportunity for Alafair to broaden VersaWrap's reach to Premier members, clinicians, and, most importantly, patients nationwide. We anticipate this agreement to further fuel our momentum and enable us to continue delivering over 100% year-over-year growth."
“我們很榮幸Premier及其成員審查了我們的技術，並授予Alafair協議，” Alafair Biosciences的總裁兼首席執行官John Joyoprayitno表示。“該協議爲Alafair提供了一個有意義的機會，將VersaWrap覆蓋到Premier成員、臨床醫生、最重要的是全國患者。我們預計這個協議將進一步推動我們的勢頭，並使我們能夠繼續提供超過100%的年度增長。”
Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 300,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting, and other services, Premier enables better care and outcomes at a lower cost.
Premier是一家領先的醫療保健改進公司，聯合約4,350家美國醫院和30萬其他醫療服務提供商，以改變醫療業。通過整合數據和分析、協同作用、供應鏈解決方案、諮詢和其他服務，Premier使患者獲得更好的護理和預後，降低成本。
About Alafair Biosciences, Inc.
關於Alafair Biosciences，Inc。
Alafair is a privately held medical device company developing and marketing an innovative product portfolio based on its proprietary hydrogel technology. The mission of Alafair is to revolutionize surgical care with our versatile hydrogel technology, delivering unparalleled value to patients, surgeons, and healthcare facilities by enhancing soft tissue protection and by elevating patient outcomes. Alafair products are distributed through a dispersed network of independent distributors across the United States.
Alafair是一傢俬人持有的醫療器械公司，開發和營銷基於其專有的水凝膠技術的創新產品組合。Alafair的使命是通過我們多用途的水凝膠技術革新外科護理，通過提高軟組織保護和提升患者預後，爲患者、外科醫生和醫療保健機構提供無與倫比的價值。Alafair產品通過分散的美國獨立經銷商網絡分銷。
About VersaWrap Hydrogel Sheet
關於VersaWrap水凝膠片
VersaWrap is an FDA-cleared medical device implant (not tissue) comprising hyaluronic acid (HA) and alginate that provides a gelatinous encasement for peripheral nerves, tendons, and surrounding tissues such as ligaments and skeletal muscles. Our innovative technology allows tissues to glide and to remain untethered, thereby reducing reoperations and improving patient outcomes. VersaWrap offers unique surgical flexibility as the only tendon and nerve protector that can be delivered either as a sheet or as a flowable gel.
VersaWrap是經過FDA審批的醫療器械植入物（不是組織），包括透明質酸（HA）和海藻酸鹽，爲周圍神經、肌腱以及周圍組織如韌帶和骨骼肌提供一種明膠封裝。我們的創新技術可以使組織滑動並保持脫節，從而減少再次手術，改善患者預後。VersaWrap在提供唯一的腱和神經保護器方面具有獨特的外科靈活性，可以作爲片狀或流動凝膠傳遞。
SOURCE Alafair Biosciences, Inc.
資料來源：Alafair Biosciences，Inc。
譯文內容由第三人軟體翻譯。